Abbott Laboratories Stock Forecast for 2023 - 2025 - 2030
Updated on 01/31/2023
Abbott Laboratories Stock Forecast and Price Target
Abbott Laboratories's stock price reaches the average target of $125.00 by 2024 as expected recently by fiveteen notable experts, there would be a potential upside of approximately 13.07% from the last closing price in January, 2023. This possible increase is based on a high estimate of $140.00 and a low estimate of $104.00. If you are interested in ABT stock, it is important to also consider its competitors.
13.07% Upside
Abbott Laboratories Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Abbott Laboratories's Price has grown by 23.77%, rising from $86.02 to $106.47. For next year, analysts predict Fair Value of $132.75, which would mean an increase of 24.69%. Over the next eight years, experts predict that Abbott Laboratories's Fair Value will grow at a rate of 59.87%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ISRG Stock Forecast | Intuitive Surgical Inc | Outperform |
15
|
$245.69 | $273.80 | 14.78% |
| BSX Stock Forecast | Boston Scientific | Outperform |
15
|
$46.24 | $50.77 | 8.13% |
| DXCM Stock Forecast | DexCom | Outperform |
16
|
$107.09 | $121.12 | 17.19% |
| RMD Stock Forecast | ResMed | Outperform |
17
|
$228.37 | $251.67 | 10.57% |
| PODD Stock Forecast | Insulet | Outperform |
15
|
$287.32 | $302.13 | 11.37% |
Abbott Laboratories Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Abbott Laboratories's Revenue has grown by 135014318.25%, rising from $31.90B to $43075.00T. For the following year, the 23 analysts predict that Abbott Laboratories's Revenue will drop by 100.00%, reaching $41.39B. In 2030, the professionals' prediction is that ABT's Revenue will decrease by 100.00%, reaching $48.89B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| NYSE:VAR Stock Forecast | Varian Medical Systems | - |
16
|
$0.00 | $0.00 | 0.00% |
| MASI Stock Forecast | Masimo | Outperform |
14
|
$170.08 | $166.14 | -0.05% |
| SWAV Stock Forecast | ShockWave Medical | Outperform |
4
|
$187.93 | $0.00 | -4.22% |
Abbott Laboratories Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Abbott Laboratories's Dividend per Share has grown, rising from $1.32 to $2.04 – a growth of 54.55%. In the following year, the 10 analysts surveyed believe that Abbott Laboratories's Dividend per Share will decrease by 3.92%, reaching $1.96. For the next eight years, the forecast is for Dividend per Share to grow by 24.75%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| LVGO Stock Forecast | Livongo Health | - |
0
|
$0.00 | $0.00 | 0.00% |
| INSP Stock Forecast | Inspire Medical Systems | Outperform |
6
|
$253.06 | $0.00 | 18.55% |
| CMD Stock Forecast | Cantel Medical | - |
17
|
$0.09 | $85.00 | 155222.22% |
Abbott Laboratories Free Cash Flow Forecast for 2023 - 2025 - 2030
Abbott Laboratories's Free Cash Flow has seen impressive growth In the last three years, rising from $4.50B to $11698.00T – a growth of 260071000.82%. According to the 6 analysts polled, in the next year, Abbott Laboratories's Free Cash Flow will fall by 100.00%, reaching $8.56B. By 2030, professionals believe that Abbott Laboratories's Free Cash Flow will have decreased by 100.00%, falling to $10.97B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| AXNX Stock Forecast | Axonics | Buy |
7
|
$62.69 | $0.00 | 14.85% |
| IRTC Stock Forecast | iRhythm Technologies | Hold |
11
|
$98.30 | $0.00 | 56.66% |
| CNMD Stock Forecast | CONMED | Outperform |
16
|
$95.76 | $145.00 | 25.31% |
Abbott Laboratories Net Income Forecast for 2023 - 2025 - 2030
Abbott Laboratories's Net Income has grown In the last three years, rising from $3.69B to $7071.00T – a growth of 191781836.53%. The next year, 19 experts forecast that Abbott Laboratories's Net Income will decrease by 100.00%, reaching $8.79B. In 2030, professionals predict that Abbott Laboratories's Net Income will decrease by 100.00%, reaching $11.30B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| TNDM Stock Forecast | Tandem Diabetes Care | Outperform |
9
|
$40.74 | $127.93 | 125.82% |
| ITGR Stock Forecast | Integer Holdings | Buy |
16
|
$65.81 | $111.33 | 65.63% |
| GNMK Stock Forecast | GenMark Diagnostics | - |
2
|
$0.00 | $24.05 | 0.00% |
Abbott Laboratories EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Abbott Laboratories's EBITDA has grown by 158061925.48%, rising from $7.77B to $12283.00T. For the next year, 11 analysts project Abbott Laboratories's EBITDA to drop by 100.00%, reaching $11.94B. By 2030, professionals believe that Abbott Laboratories's EBITDA will decrease by 100.00%, reaching $13.04B – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| NVRO Stock Forecast | Nevro | Hold |
6
|
$36.72 | $69.50 | 75.65% |
| SILK Stock Forecast | Silk Road Medical, Inc | Outperform |
7
|
$54.36 | $0.00 | -4.34% |
| TMDX Stock Forecast | TransMedics Group | Outperform |
8
|
$63.02 | $0.00 | -55.57% |
Abbott Laboratories EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Abbott Laboratories's EBIT has grown, moving from $4.76B to $9.22B – an increase of 93.78%. In the next year, analysts predict that EBIT will jump to $10.32B – up 11.95% from the current level. Looking ahead to eight years, experts forecast that EBIT will grow by 43.17%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| NTUS Stock Forecast | Natus Medical | - |
14
|
$32.96 | $36.00 | 70.27% |
| CUTR Stock Forecast | Cutera | Buy |
6
|
$34.83 | $42.20 | 123.94% |
| SENS Stock Forecast | Senseonics Holdings | Hold |
6
|
$1.13 | $0.00 | 121.24% |
Abbott Laboratories EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, Abbott Laboratories's EPS has grown by 23.77%, rising from $3.24 to $4.01. For next year, analysts predict EPS of $5.00, which would mean an increase of 24.69%. Over the next eight years, experts predict that Abbott Laboratories's EPS will grow at a rate of 59.87%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| INGN Stock Forecast | Inogen | Outperform |
8
|
$22.45 | $44.00 | 42.54% |
| QTRX Stock Forecast | Quanterix | Buy |
11
|
$13.88 | $0.00 | 162.97% |
| VRAY Stock Forecast | ViewRay | Outperform |
7
|
$4.42 | $0.00 | 92.31% |